EA201400568A1 - ALBUMINS CONNECTING ANTIBODIES AND THEIR CONNECTING FRAGMENTS - Google Patents
ALBUMINS CONNECTING ANTIBODIES AND THEIR CONNECTING FRAGMENTSInfo
- Publication number
- EA201400568A1 EA201400568A1 EA201400568A EA201400568A EA201400568A1 EA 201400568 A1 EA201400568 A1 EA 201400568A1 EA 201400568 A EA201400568 A EA 201400568A EA 201400568 A EA201400568 A EA 201400568A EA 201400568 A1 EA201400568 A1 EA 201400568A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- seq
- variable domain
- antibodies
- fragments
- application
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title abstract 4
- 102000009027 Albumins Human genes 0.000 title 1
- 108010088751 Albumins Proteins 0.000 title 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 102000007562 Serum Albumin Human genes 0.000 abstract 1
- 108010071390 Serum Albumin Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
Abstract
В заявке описано связывающее сывороточный альбумин антитело или его фрагмент, содержащее/содержащий вариабельный домен тяжелой цепи, который имеет последовательность, представленную в SEQ ID NO: 1 или SEQ ID NO: 2, и/или содержащее/содержащий вариабельный домен легкой цепи, который имеет последовательность, представленную в SEQ ID NO: 3 или SEQ ID NO: 4, в частности, содержащее/содержащий вариабельный домен тяжелой цепи и вариабельный домен легкой цепи, которые имеют последовательности, представленные в SEQ ID NO: 1 и SEQ ID NO: 3, или вариабельный домен тяжелой цепи и вариабельный домен легкой цепи, которые имеют последовательности, представленные в SEQ ID NO: 2 и SEQ ID NO: 4. В заявке описаны также полинуклеотиды, кодирующие антитела или фрагменты, векторы, которые их содержат, и клетки-хозяева, обладающие способностью экспрессировать полинуклеотиды. В заявке описаны также фармацевтические композиции, содержащие антитела или фрагменты, и терапевтическое применение любого из них.The application describes a serum albumin binding antibody or its fragment containing / containing the variable domain of the heavy chain, which has the sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2, and / or containing / containing the variable domain of the light chain, which has the sequence presented in SEQ ID NO: 3 or SEQ ID NO: 4, in particular, containing / containing the variable domain of the heavy chain and the variable domain of the light chain, which have the sequences presented in SEQ ID NO: 1 and SEQ ID NO: 3, or heavy chain variable domain light chain variable domain, which have the sequences shown in SEQ ID NO: 2 and SEQ ID NO: 4. The application also describes polynucleotides encoding the antibodies or fragments, vectors containing them and host cells having the ability to express the polynucleotides. The application also describes pharmaceutical compositions containing antibodies or fragments, and therapeutic use of any of them.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161558559P | 2011-11-11 | 2011-11-11 | |
| PCT/EP2012/072335 WO2013068571A1 (en) | 2011-11-11 | 2012-11-09 | Albumin binding antibodies and binding fragments thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201400568A1 true EA201400568A1 (en) | 2014-12-30 |
| EA033766B1 EA033766B1 (en) | 2019-11-22 |
Family
ID=47358092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201400568A EA033766B1 (en) | 2011-11-11 | 2012-11-09 | Albumin binding antibodies and binding fragments thereof |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9803004B2 (en) |
| EP (1) | EP2776466B1 (en) |
| JP (1) | JP6411214B2 (en) |
| KR (1) | KR102048382B1 (en) |
| CN (1) | CN103946237B (en) |
| AU (1) | AU2012335496B2 (en) |
| BR (1) | BR112014011304B1 (en) |
| CA (1) | CA2856216C (en) |
| CY (1) | CY1119647T1 (en) |
| DK (1) | DK2776466T3 (en) |
| EA (1) | EA033766B1 (en) |
| ES (1) | ES2649098T3 (en) |
| HR (1) | HRP20171608T1 (en) |
| HU (1) | HUE037142T2 (en) |
| IL (1) | IL232226B (en) |
| IN (1) | IN2014DN03451A (en) |
| LT (1) | LT2776466T (en) |
| MX (1) | MX351502B (en) |
| NO (1) | NO2839445T3 (en) |
| PL (1) | PL2776466T3 (en) |
| PT (1) | PT2776466T (en) |
| SG (1) | SG11201401649VA (en) |
| SI (1) | SI2776466T1 (en) |
| WO (1) | WO2013068571A1 (en) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA112203C2 (en) | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Fusion protein of a biospecific antibody that binds to human OX40 and serum human albumin |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| GB201223276D0 (en) | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
| JP6422977B2 (en) * | 2013-08-30 | 2018-11-14 | エイプリルバイオ カンパニー リミテッド | Antiserum albumin FAB effector partial fusion construct and method for producing the same |
| GB201320066D0 (en) | 2013-11-13 | 2013-12-25 | Ucb Pharma Sa | Biological products |
| GB201411320D0 (en) * | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| GB201506868D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method for protein purification |
| EA201792451A1 (en) | 2015-05-07 | 2018-05-31 | Агенус Инк. | ANTIBODIES TO OX40 AND METHODS OF THEIR APPLICATION |
| GB201508180D0 (en) | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
| EP3319983B1 (en) | 2015-07-06 | 2026-01-28 | UCB Biopharma SRL | Tau-binding antibodies |
| MA42380A (en) | 2015-07-06 | 2018-05-16 | Ucb Biopharma Sprl | ANTIBODIES BONDING TO TAU |
| WO2017060242A1 (en) | 2015-10-05 | 2017-04-13 | Ucb Biopharma Sprl | Molecular signatures for use in diagnosis and response to treatment analysis of autoimmune diseases |
| IL299072A (en) | 2015-12-02 | 2023-02-01 | Memorial Sloan Kettering Cancer Center | Antibodies and methods of use thereof |
| GB201602938D0 (en) | 2016-02-19 | 2016-04-06 | Ucb Biopharma Sprl | Protein purification |
| CA3022494A1 (en) * | 2016-05-01 | 2017-11-09 | Ucb Biopharma Sprl | Affinity engineered serum protein carrier binding domain |
| GB201610198D0 (en) * | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
| CA3041340A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| EP4467565A3 (en) | 2016-12-21 | 2025-03-12 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| EP3583125B1 (en) | 2017-02-16 | 2025-01-22 | Sonnet BioTherapeutics, Inc. | Albumin binding domain fusion proteins |
| ES3015094T3 (en) * | 2017-06-05 | 2025-04-29 | Numab Therapeutics AG | Anti-hsa antibodies |
| WO2018224439A1 (en) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-hsa antibodies |
| GB201711481D0 (en) | 2017-07-17 | 2017-08-30 | Ucb Biopharma Sprl | Protein purification |
| KR102204315B1 (en) * | 2018-11-16 | 2021-01-18 | 한국세라믹기술원 | Affibody specific to human serum albumin and its use |
| AU2020326087A1 (en) | 2019-08-02 | 2021-12-16 | UCB Biopharma SRL | Methods for purifying antibodies |
| CN112409480B (en) * | 2019-08-20 | 2024-08-27 | 四川科伦博泰生物医药股份有限公司 | Serum albumin binding proteins and uses thereof |
| GB201919062D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Antibody |
| GB201919058D0 (en) * | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibodies |
| GB201919061D0 (en) * | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibody |
| GB202001447D0 (en) | 2020-02-03 | 2020-03-18 | Ucb Biopharma Sprl | Antibodies |
| CN115667298A (en) | 2020-03-27 | 2023-01-31 | Ucb生物制药有限责任公司 | autonomous bulge domain peptide |
| KR102367488B1 (en) * | 2020-06-29 | 2022-02-25 | 주식회사 프로테인웍스 | A analysis method of single chain antibody fragment(scFv)-albumin drug conjugate |
| EP4229086A1 (en) | 2020-10-15 | 2023-08-23 | UCB Biopharma SRL | Binding molecules that multimerise cd45 |
| JP2023551981A (en) | 2020-12-07 | 2023-12-13 | ユーシービー バイオファルマ エスアールエル | Multispecific antibodies and antibody combinations |
| JP2023551983A (en) | 2020-12-07 | 2023-12-13 | ユーシービー バイオファルマ エスアールエル | Antibodies against interleukin-22 |
| CN115181751A (en) * | 2021-04-02 | 2022-10-14 | 苏州博腾生物制药有限公司 | Chimeric antigen receptors targeting albumin and methods of use thereof |
| AR125732A1 (en) | 2021-05-03 | 2023-08-09 | UCB Biopharma SRL | ANTI-TREM1 ANTIBODIES |
| TW202313685A (en) * | 2021-06-07 | 2023-04-01 | 大陸商上海濟煜醫藥科技有限公司 | Anti-human serum albumin antigen binding protein |
| GB202111905D0 (en) | 2021-08-19 | 2021-10-06 | UCB Biopharma SRL | Antibodies |
| AU2023291634C9 (en) | 2022-06-15 | 2026-01-22 | UCB Biopharma SRL | Follistatin fusion proteins |
| AU2023291641A1 (en) | 2022-06-15 | 2024-12-12 | Five Prime Therapeutics, Inc. | Fusion protein for the prevention, treatment or amelioration of kidney diseases |
| GB202318820D0 (en) | 2023-12-08 | 2024-01-24 | UCB Biopharma SRL | Antibodies |
| US12134635B1 (en) | 2023-12-29 | 2024-11-05 | Sonnet BioTherapeutics, Inc. | Interleukin 18 (IL-18) variants and fusion proteins comprising same |
| WO2025238133A1 (en) | 2024-05-17 | 2025-11-20 | UCB Biopharma SRL | Multispecific antibody with binding specificity for il-11 and il-17 |
| WO2025238135A2 (en) | 2024-05-17 | 2025-11-20 | UCB Biopharma SRL | Antibody with binding specificity for il-11 |
| WO2025248017A1 (en) | 2024-05-31 | 2025-12-04 | UCB Biopharma SRL | Method of purifying recombinant proteins |
| KR20250175017A (en) | 2024-06-05 | 2025-12-16 | 주식회사 엔바이오스 | Antibody specifically binding to HSA and use thereof |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| AU4308689A (en) | 1988-09-02 | 1990-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| ES2052027T5 (en) | 1988-11-11 | 2005-04-16 | Medical Research Council | IMMUNOGLOBULINE VARIABLE DOMAIN SEQUENCE CLONING. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| SE509359C2 (en) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Use of stabilized protein or peptide conjugates for the preparation of a drug |
| US6267964B1 (en) | 1989-08-01 | 2001-07-31 | Affibody Technology Sweden Ab | Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| DK0463151T3 (en) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Generation of xenogenic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69127627T2 (en) | 1990-08-29 | 1998-02-19 | Genpharm Int | Production and Use Non-human transgene heterologous antibodies for production |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| DE69129154T2 (en) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES |
| ATE414768T1 (en) | 1991-04-10 | 2008-12-15 | Scripps Research Inst | LIBRARIES OF HETERODIMER RECEPTORS USING PHAGEMIDS |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
| ES2341666T3 (en) | 1991-12-02 | 2010-06-24 | Medimmune Limited | PRODUCTION OF AUTHORTIC BODIES OF REPERTORIES OF ANTIQUE RPOS SEGMENTS EXPRESSED ON THE FAGOS SURFACE. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| DK1621554T4 (en) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobulins devoid of light chains |
| EP0733070A1 (en) | 1993-12-08 | 1996-09-25 | Genzyme Corporation | Process for generating specific antibodies |
| DE69531148T2 (en) | 1994-01-31 | 2004-04-29 | Trustees Of Boston University, Boston | LIBRARIES MADE OF POLYCLONAL ANTIBODIES |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| JP2978435B2 (en) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | Method for producing acryloxypropyl silane |
| AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| DE19653722C2 (en) | 1996-12-10 | 2000-06-29 | Brose Fahrzeugteile | Adjustment device acting on both sides |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| WO1998037200A2 (en) | 1997-02-21 | 1998-08-27 | Genentech, Inc. | Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies |
| GB9720054D0 (en) | 1997-09-19 | 1997-11-19 | Celltech Therapeutics Ltd | Biological products |
| DE69922159T2 (en) | 1998-01-23 | 2005-12-01 | Vlaams Interuniversitair Instituut Voor Biotechnologie | MULTI-PURPOSE ANTIBODY DERIVATIVES |
| GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
| ATE422369T1 (en) | 1999-12-24 | 2009-02-15 | Genentech Inc | METHODS AND COMPOSITIONS FOR EXTENSING THE DISPOSAL HALF-LIFE OF BIODACTIC COMPOUNDS |
| AU2002335930B2 (en) | 2001-03-09 | 2005-07-28 | Morphosys Ag | Serum albumin binding moieties |
| AU2003245664A1 (en) | 2002-06-21 | 2004-01-06 | Dyax Corporation | Serum protein-associated target-specific ligands and identification method therefor |
| AU2003244817B2 (en) | 2002-06-28 | 2010-08-26 | Domantis Limited | Antigen-binding immunoglobulin single variable domains and dual-specific constructs |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| PT1570267E (en) | 2002-12-03 | 2012-01-03 | Ucb Pharma Sa | Assay for identifying antibody producing cells |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| SI1644412T2 (en) | 2003-07-01 | 2018-11-30 | Ucb Biopharma Sprl | Modified antibody fab fragments |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| BRPI0511755A (en) | 2004-06-01 | 2008-01-02 | Domantis Ltd | drug compositions, fusions and conjugates and methods of production, treatment and use |
| WO2006059105A2 (en) | 2004-12-01 | 2006-06-08 | Health Protection Agency | Non-cytotoxic Protein Conjugates |
| GB0506912D0 (en) | 2005-04-05 | 2005-05-11 | Celltech R&D Ltd | Biological products |
| EP2535350B1 (en) | 2007-09-26 | 2018-01-24 | UCB Biopharma SPRL | Dual specificity antibody fusions |
| HRP20170374T1 (en) | 2008-09-26 | 2017-05-05 | Ucb Biopharma Sprl | Biological products |
| SG2014014708A (en) | 2009-02-17 | 2014-05-29 | Ucb Pharma Sa | Antibody molecules having specificity for human ox40 |
| EA201270174A1 (en) | 2009-07-16 | 2012-07-30 | Глэксо Груп Лимитед | SEPARATE BINDING VARIABLE DOMAINS WITH IMPROVED PROPERTIES DIRECTED AGAINST SERUM ALBUMIN |
| WO2011030107A1 (en) * | 2009-09-10 | 2011-03-17 | Ucb Pharma S.A. | Multivalent antibodies |
| GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| GB0920127D0 (en) * | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
-
2012
- 2012-11-09 PL PL12801467T patent/PL2776466T3/en unknown
- 2012-11-09 SG SG11201401649VA patent/SG11201401649VA/en unknown
- 2012-11-09 LT LTEP12801467.7T patent/LT2776466T/en unknown
- 2012-11-09 ES ES12801467.7T patent/ES2649098T3/en active Active
- 2012-11-09 EA EA201400568A patent/EA033766B1/en not_active IP Right Cessation
- 2012-11-09 JP JP2014540494A patent/JP6411214B2/en active Active
- 2012-11-09 SI SI201231119T patent/SI2776466T1/en unknown
- 2012-11-09 US US14/356,181 patent/US9803004B2/en active Active
- 2012-11-09 KR KR1020147015678A patent/KR102048382B1/en active Active
- 2012-11-09 AU AU2012335496A patent/AU2012335496B2/en active Active
- 2012-11-09 WO PCT/EP2012/072335 patent/WO2013068571A1/en not_active Ceased
- 2012-11-09 HR HRP20171608TT patent/HRP20171608T1/en unknown
- 2012-11-09 HU HUE12801467A patent/HUE037142T2/en unknown
- 2012-11-09 CN CN201280055064.0A patent/CN103946237B/en active Active
- 2012-11-09 IN IN3451DEN2014 patent/IN2014DN03451A/en unknown
- 2012-11-09 MX MX2014005546A patent/MX351502B/en active IP Right Grant
- 2012-11-09 EP EP12801467.7A patent/EP2776466B1/en active Active
- 2012-11-09 BR BR112014011304-1A patent/BR112014011304B1/en active IP Right Grant
- 2012-11-09 CA CA2856216A patent/CA2856216C/en active Active
- 2012-11-09 PT PT128014677T patent/PT2776466T/en unknown
- 2012-11-09 DK DK12801467.7T patent/DK2776466T3/en active
-
2013
- 2013-04-12 NO NO13716781A patent/NO2839445T3/no unknown
-
2014
- 2014-04-24 IL IL23222614A patent/IL232226B/en active IP Right Grant
-
2017
- 2017-10-27 US US15/795,874 patent/US10023631B2/en active Active
- 2017-11-22 CY CY20171101222T patent/CY1119647T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201400568A1 (en) | ALBUMINS CONNECTING ANTIBODIES AND THEIR CONNECTING FRAGMENTS | |
| PE20150023A1 (en) | ST2 ANTIGEN BINDING PROTEINS | |
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| EA201490053A1 (en) | ANTIBODIES THAT ARE BIND OX40 AND THEIR APPLICATION | |
| MX347954B (en) | Antibody drug conjugates (adc) that bind to 191p4d12 proteins. | |
| UA106607C2 (en) | SPECIFIC BINDING PROTEINS AND THEIR APPLICATIONS | |
| EA201291067A1 (en) | HUMANIZED ANTIGENSORATING PROTEINS FOR MYOSTATIN | |
| EP3255063A3 (en) | Antibodies to matrix metalloproteinase 9 | |
| PH12016501691A1 (en) | Antibodies to matrix metalloproteinase 9 | |
| EA201491494A1 (en) | NACELIVANIE NA GLIKANY HONDROITINSULFATY | |
| EA201491524A1 (en) | RELATING ERYTHROCYTES THERAPEUTIC TOOLS | |
| EA201491214A1 (en) | COMPOSITIONS AND METHODS OF APPLICATION OF ANTIBODIES AIMED AT THE FACTOR P | |
| PH12014501931A1 (en) | Antibodies to matrix metalloproteinase 9 | |
| EA201291065A1 (en) | ANTIBODIES AGAINST VLA-4 | |
| MX388698B (en) | BINDING MOLECULES, ESPECIALLY ANTIBODIES, BOUND TO L1CAM (CD171). | |
| WO2012091564A3 (en) | A cross linking polypeptide comprising an hexameric single chain antibody binding mhc-mage complex that induces apoptosis | |
| EA201790816A1 (en) | ANTIBODIES THAT ARE ASSOCIATED WITH CCR6 AND APPLICATION OPTIONS FOR THE INDICATED ANTIBODIES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |